Burosumab Biosimilar - Research Grade

Human

FGF23

>1mg/ml

Human IgG1 (E356D/M358L)-kappa

https://www.imgt.org/mAb-DB/

ICH3002

Q9GZV9

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of burosumab, a fully human IgG1 monoclonal antibody directed against fibroblast growth factor 23 (FGF23). It is supplied for research use only and is not the clinical product; it is not intended for human or veterinary use. Built around the FGF23 target, it reproduces the antigen-binding behavior of the originator, making it a convenient tool for studying FGF23 biology and antibody-mediated neutralization in controlled settings. Typical research applications include use as an isotype-matched binding and neutralization reagent, a positive control in FGF23 assay development, a benchmarking standard in comparability and analytical work, and a reference antibody in phosphate/vitamin D endocrine pathway studies. The material is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support in-vitro assays and preclinical model work. As a research-grade analog it enables cost-effective, reproducible experimentation without sourcing clinical drug product. Fibroblast growth factor 23 (FGF23; UniProt Q9GZV9) is a bone-derived endocrine hormone secreted mainly by osteocytes and osteoblasts that regulates systemic phosphate and vitamin D homeostasis. Acting on kidney FGF receptors with the obligate co-receptor alpha-Klotho, FGF23 reduces renal phosphate reabsorption by downregulating the sodium-phosphate cotransporters NaPi-2a and NaPi-2c, and it suppresses 1-alpha-hydroxylase (CYP27B1) while inducing 24-hydroxylase (CYP24A1), lowering active 1,25-dihydroxyvitamin D. The intact protein is proteolytically cleaved at an RXXR furin site; the mutation-prone R176/R179 region governs stability of the active hormone. Excess intact FGF23 drives renal phosphate wasting and hypophosphatemia, as seen in X-linked hypophosphatemia and tumor-induced osteomalacia. Neutralizing FGF23 restores phosphate retention and vitamin D activation, which is the rationale for anti-FGF23 antibodies.

Phosphatonin, Tumor-derived hypophosphatemia-inducing factor, Fibroblast growth factor 23, HYPF

Detects human FGF23

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.